Ariel G. Notcovich is an accomplished life science executive, with a wide experience in all aspects and stages of product development for life science markets, having worked in startup as well as in corporate environments. Ariel founded ProteOptics during his graduate studies in Physics at the Technion-Israel Institute of Technology and served as its CTO and CEO. The company developed a multichannel Surface Plasmon Resonance imaging system for the label-free analysis of molecular interactions. ProteOptics was acquired by Bio-Rad Laboratories. Ariel successfully managed the integration, establishing his team as the innovation center for Bio-Rad Life Sciences Group. As a visionary and entrepreneurial leader of Bio-Rad R&D, he created the Protein Technologies R&D group to develop innovative products for life sciences markets. Products developed in Ariel’s group included systems, instrumentation, software, consumables and reagents for imaging, chromatography, gel electrophoresis and blotting, protein interactions and other product lines.


Gayle is responsible for finance and general business activities at Biodesy. Her career has been focused in early stage life science companies. Prior to joining Biodesy, she was VP of Finance at Isostent, CFO at Radiant Medical, and sole proprietor of her own consulting practice, working with numerous life science client companies and helping raise more than $100M in venture funding.  Gayle has led the finance, accounting, human resources, facilities, information technology (IT), and manufacturing engineering functions.  She received her Master’s Degree in Industrial Administration (MSIA) from the Tepper School at Carnegie Mellon University in Pittsburgh, Pennsylvania and her BA in Economics, magna cum laude, from the University of Washington in Seattle, Washington.


Lou leads all engineering activities at Biodesy. He has extensive experience in imaging systems, optical detection, and microfluidics for life science applications, and has developed numerous successful products for the medical diagnostic and bioanalytical research markets. As a consultant, he has designed FDA-cleared products for digital pathology and point-of-care diagnostic testing. He has also held senior engineering management roles in several companies, such as On-Q-ity (formerly CELLective DX), Nanoplex Technologies, and SurroMed, where he has managed teams developing microfluidic devices and instrumentation for analyzing circulating tumor cells in blood samples, automated manufacturing of microparticles and nanoparticles for multiplexed immunoassays, and automated laser-scanning cytometry systems for biomarker discovery and clinical diagnostics. The author or co-author of federal grants totaling $13 million, he holds 15 U.S. patents covering optical instrumentation, nanoparticle manufacturing techniques, and electronic circuitry for communications systems. He received his B.S. and M.S. in Electrical Engineering from Stanford University.